Citation Information :
Sharma M, Shroff D, Narain S, Shroff CM, Gupta C. Combined Treatment with Intravitreal Bevacizumab and Intravitreal Triamcinolone in Retinal Vein Occlusion in Indian Eyes. J Postgrad Med Edu Res 2019; 53 (2):75-78.
Purpose: To study therapeutic efficacy of combination of intravitreal triamcinolone acetonide and intravitreal bevacizumab for treatment of macular edema associated with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).
Method: This prospective interventional study included 20 eyes of 20 patients with fresh retinal vein occlusion (RVO) of less than three months duration. Treatment involved intravitreal injection with 1.25 mg bevacizumab and 1mg triamcinolone acetonide.
Result: The mean age of patients was 63.81 years. There were 10 patients each of BRVO and CRVO. Both groups showed significant improvement in mean baseline visual acuity, however BRVO patients fared better than CRVO patients at all visits. Mean baseline central macular thickness (CMT) in BRVO and CRVO patients was 381.70 microns, and 572.50 microns, respectively with mean reduction of 131.40 and 182.1 microns, respectively. This reduction was significant at all visits during the course of the follow-up.
Rise in intraocular pressure (IOP) ≥ 21 mm Hg was found in 5 BRVO and 4 CRVO patients. Cataract development and progression was found 2 BRVO and 1 CRVO patient. There was no case of retinal detachment or endophthalmitis.
Conclusion: Combined treatment with intravitreal bevacizumab and intravitreal triamcinolone acetonide causes structural and functional improvement in form of reduction of macular edema and improvement in visual acuity in eyes with both BRVO and CRVO.
Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005;24:493-519.
Bearelly S, Fekrat S. Controversy in the management of retinal venous occlusive disease. Int Ophthalmol Clin 2004;44(4):85-102.
Mohamed Q, McIntosh RL, Saw SM, et al. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:507-519,524.
McIntosh RL, Mohamed Q, Saw SM, et al. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:835-854.
The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98:271-282.
The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M report. Ophthalmology 1995; 102:1425-1433.
Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 2005;83(5): 600-604.
Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240(9):782-783.
Çekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005; 25:851-855.
Çakýr M, Doðan M, Bayraktar Z, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 2008;28:465-442.
Campochiari PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmol 2011;118:1102-1111.
Campochiaro PA, Brown DM, Awh CC, et al. Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study. Ophthalmology 2011 Oct;118(10):2041-2049.
Stahl A, Agostini H, Hansen LL, et al. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefe's Clin Exp Ophthalmo 2007;245:1429-1436.
Jaissle GB, Leiritz M, Geliþken F, et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefe's Clin Exp Ophthalmol 2009;247:27-33.
Vinten M, Larsen M, Lund-Anderson H, et al. Short-term effects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular edema. Acta Ophthalmol Scand; 85: 21-26.
Zhang X, Bao S, Lai D, et al. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008;57(4):1026-1033.
Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retin. 2006;26(8):859-870.
Ehrlich R, Ciulla TA, Moss AM, et al. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol. DOI 10.1007/s00417-009-1211-6.
Çekiç O, Çakýr M, Yazýcý AT, et al. A Comparison of Three Different Intravitreal Treatment Modalities of Macular Edema Due to Branch Retinal Vein Occlusion Current Eye Research 2010;35(10): 925-929.
Rath EZ, Frank RN, Shin DH, et al. Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 1992;99:509-514.
Elman MJ, Bhatt AK, Quinlan PM, et al. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990;97:1543-1548.
McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113-1123.e1115.
Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010; 117:1094-1101.e1095.
Morley MG, Heier JS. Yanoff & Duker: Ophthalmology, 3rd ed. 2008 Mosby, an imprint of Elsevier. p. 2134-2137.
Scott I, Van Veldhuisen P et al. SCORE Study Report 1: Baseline Associations between Central Retinal Thickness and Visual Acuity in Patients with Retinal Vein Occlusion. Ophthalmology 2009 March;116(3):504-512.
Tao Y, Hou J, Jiang YR, et al. Intravitreal bevacizumab versus triamcinolone acetonide for macular edeme due to central retinal vein occlusion. Eye (Lond) 2010 May;24(5):810-815.
Ekdawi NS, Bakri SJ. Intravitreal triamcinolone and bevacizumab combined therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. Eye 2007;21(8):1128-1130.
Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in agerelated macular degeneration? Ophthalmology 2008;115:2199-205.
Ali RI, Kapoor KG, Khan AN, et al. Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion. Indian J Ophthalmol 2014 Apr;62(4):396-399. doi: 10.4103/0301- 4738.120227.
Lee K, Jung H, Sohn J. Comparison of Injection of Intravitreal Drugs with Standard Care in Macular Edema Secondary to Branch Retinal Vein Occlusion. Korean Journal of Ophthalmology: KJO 2014;28(1):19-25.
Moon J, Kim M, Sagong M. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye (Lond) 2016 Aug;30(8):1084-1090.
Motarjemizadeh G, Rajabzadeh M, Aidenloo NS, et al. Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with central retinal vein occlusion: A randomized clinical trial. Electron Physician 2017 Aug 1;9(8):5068-5074.